Go Pro
→ Trump’s New Currency Reset (From Porter & Company) (Ad)tc pixel Free TTOO Stock Alerts

T2 Biosystems (TTOO) Competitors

T2 Biosystems logo
$0.0010 +0.00 (+100.00%)
As of 02:13 PM Eastern
Compare

TTOO vs. SDCCQ, GMVDF, VRAYQ, AFIB, and UTRS

Should you buy T2 Biosystems stock or one of its competitors? T2 Biosystems's main competitors and comparable companies include SmileDirectClub (SDCCQ), G Medical Innovations (GMVDF), ViewRay (VRAYQ), Acutus Medical (AFIB), and Minerva Surgical (UTRS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does T2 Biosystems compare to SmileDirectClub?

SmileDirectClub (NASDAQ:SDCCQ) and T2 Biosystems (NASDAQ:TTOO) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability, valuation and media sentiment.

In the previous week, SmileDirectClub's average media sentiment score of 0.00 equaled T2 Biosystems'average media sentiment score.

Company Overall Sentiment
SmileDirectClub Neutral
T2 Biosystems Neutral

0.1% of SmileDirectClub shares are owned by institutional investors. Comparatively, 23.2% of T2 Biosystems shares are owned by institutional investors. 64.7% of SmileDirectClub shares are owned by company insiders. Comparatively, 0.0% of T2 Biosystems shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

SmileDirectClub has a beta of 1.31, meaning that its share price is 31% more volatile than the broader market. Comparatively, T2 Biosystems has a beta of 7.75, meaning that its share price is 675% more volatile than the broader market.

SmileDirectClub has a net margin of 0.00% compared to T2 Biosystems' net margin of -563.16%.

Company Net Margins Return on Equity Return on Assets
SmileDirectClubN/A N/A N/A
T2 Biosystems -563.16%N/A -174.06%

T2 Biosystems has lower revenue, but higher earnings than SmileDirectClub. SmileDirectClub is trading at a lower price-to-earnings ratio than T2 Biosystems, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SmileDirectClub$470.74M0.00-$86.40M-$0.13N/A
T2 Biosystems$7.68M0.00-$50.08M-$3.89N/A

Summary

SmileDirectClub and T2 Biosystems tied by winning 5 of the 10 factors compared between the two stocks.

How does T2 Biosystems compare to G Medical Innovations?

G Medical Innovations (NASDAQ:GMVDF) and T2 Biosystems (NASDAQ:TTOO) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment and risk.

6.0% of G Medical Innovations shares are owned by institutional investors. Comparatively, 23.2% of T2 Biosystems shares are owned by institutional investors. 37.1% of G Medical Innovations shares are owned by insiders. Comparatively, 0.0% of T2 Biosystems shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

G Medical Innovations has a net margin of 0.00% compared to T2 Biosystems' net margin of -563.16%.

Company Net Margins Return on Equity Return on Assets
G Medical InnovationsN/A N/A N/A
T2 Biosystems -563.16%N/A -174.06%

G Medical Innovations has higher earnings, but lower revenue than T2 Biosystems.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
G Medical Innovations$4.42M0.01-$24.63MN/AN/A
T2 Biosystems$7.68M0.00-$50.08M-$3.89N/A

In the previous week, G Medical Innovations' average media sentiment score of 0.00 equaled T2 Biosystems'average media sentiment score.

Company Overall Sentiment
G Medical Innovations Neutral
T2 Biosystems Neutral

G Medical Innovations has a beta of 29.41, suggesting that its stock price is 2,841% more volatile than the broader market. Comparatively, T2 Biosystems has a beta of 7.75, suggesting that its stock price is 675% more volatile than the broader market.

Summary

G Medical Innovations beats T2 Biosystems on 6 of the 8 factors compared between the two stocks.

How does T2 Biosystems compare to ViewRay?

T2 Biosystems (NASDAQ:TTOO) and ViewRay (NASDAQ:VRAYQ) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, media sentiment, dividends, profitability, institutional ownership, analyst recommendations, risk and valuation.

In the previous week, T2 Biosystems' average media sentiment score of 0.00 equaled ViewRay'saverage media sentiment score.

Company Overall Sentiment
T2 Biosystems Neutral
ViewRay Neutral

T2 Biosystems has a beta of 7.75, suggesting that its stock price is 675% more volatile than the broader market. Comparatively, ViewRay has a beta of 0.77, suggesting that its stock price is 23% less volatile than the broader market.

23.2% of T2 Biosystems shares are held by institutional investors. Comparatively, 15.5% of ViewRay shares are held by institutional investors. 0.0% of T2 Biosystems shares are held by insiders. Comparatively, 2.5% of ViewRay shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

T2 Biosystems has higher earnings, but lower revenue than ViewRay.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
T2 Biosystems$7.68M0.00-$50.08M-$3.89N/A
ViewRay$102.21M0.00-$107.33MN/AN/A

ViewRay has a net margin of 0.00% compared to T2 Biosystems' net margin of -563.16%.

Company Net Margins Return on Equity Return on Assets
T2 Biosystems-563.16% N/A -174.06%
ViewRay N/A N/A N/A

Summary

T2 Biosystems and ViewRay tied by winning 4 of the 8 factors compared between the two stocks.

How does T2 Biosystems compare to Acutus Medical?

Acutus Medical (NASDAQ:AFIB) and T2 Biosystems (NASDAQ:TTOO) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, institutional ownership, risk, media sentiment, valuation, profitability and analyst recommendations.

56.9% of Acutus Medical shares are held by institutional investors. Comparatively, 23.2% of T2 Biosystems shares are held by institutional investors. 5.2% of Acutus Medical shares are held by company insiders. Comparatively, 0.0% of T2 Biosystems shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

T2 Biosystems has higher revenue and earnings than Acutus Medical. Acutus Medical is trading at a lower price-to-earnings ratio than T2 Biosystems, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Acutus Medical$7.16M0.00-$81.66M-$0.11N/A
T2 Biosystems$7.68M0.00-$50.08M-$3.89N/A

Acutus Medical has a net margin of -272.74% compared to T2 Biosystems' net margin of -563.16%. T2 Biosystems' return on equity of 0.00% beat Acutus Medical's return on equity.

Company Net Margins Return on Equity Return on Assets
Acutus Medical-272.74% -311.64% -11.57%
T2 Biosystems -563.16%N/A -174.06%

Acutus Medical has a beta of 5.7, indicating that its share price is 470% more volatile than the broader market. Comparatively, T2 Biosystems has a beta of 7.75, indicating that its share price is 675% more volatile than the broader market.

In the previous week, Acutus Medical's average media sentiment score of 0.00 equaled T2 Biosystems'average media sentiment score.

Company Overall Sentiment
Acutus Medical Neutral
T2 Biosystems Neutral

Summary

T2 Biosystems beats Acutus Medical on 6 of the 11 factors compared between the two stocks.

How does T2 Biosystems compare to Minerva Surgical?

T2 Biosystems (NASDAQ:TTOO) and Minerva Surgical (NASDAQ:UTRS) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, media sentiment, dividends, risk, profitability and institutional ownership.

T2 Biosystems has a beta of 7.75, suggesting that its share price is 675% more volatile than the broader market. Comparatively, Minerva Surgical has a beta of 2.41, suggesting that its share price is 141% more volatile than the broader market.

23.2% of T2 Biosystems shares are owned by institutional investors. 0.0% of T2 Biosystems shares are owned by insiders. Comparatively, 8.5% of Minerva Surgical shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Minerva Surgical has a net margin of 0.00% compared to T2 Biosystems' net margin of -563.16%.

Company Net Margins Return on Equity Return on Assets
T2 Biosystems-563.16% N/A -174.06%
Minerva Surgical N/A N/A N/A

In the previous week, T2 Biosystems' average media sentiment score of 0.00 equaled Minerva Surgical'saverage media sentiment score.

Company Overall Sentiment
T2 Biosystems Neutral
Minerva Surgical Neutral

Minerva Surgical has higher revenue and earnings than T2 Biosystems. T2 Biosystems is trading at a lower price-to-earnings ratio than Minerva Surgical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
T2 Biosystems$7.68M0.00-$50.08M-$3.89N/A
Minerva Surgical$51.69M0.00-$34.11M-$1.81N/A

Summary

Minerva Surgical beats T2 Biosystems on 7 of the 9 factors compared between the two stocks.

Get T2 Biosystems News Delivered to You Automatically

Sign up to receive the latest news and ratings for TTOO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TTOO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TTOO vs. The Competition

Export
MetricT2 BiosystemsHealthcare Equipment & Supplies IndustryHealthcare SectorNASDAQ Exchange
Market Cap$21K$5.95B$7.06B$13.10B
Dividend YieldN/A1.76%2.57%10.45%
P/E Ratio0.0026.22269.0625.28
Price / Sales0.0063.24592.9687.71
Price / CashN/A33.9270.4850.90
Price / Book0.006.1012.916.24
Net Income-$50.08M$148.67M$3.45B$347.60M
7 Day PerformanceN/A1.84%1.12%1.07%
1 Month PerformanceN/A4.56%1.79%1.03%
1 Year PerformanceN/A8.67%67.69%20.77%

T2 Biosystems Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TTOO
T2 Biosystems
N/A$0.00
+100.0%		N/A-95.5%$21K$7.68MN/A180
SDCCQ
SmileDirectClub
N/A$0.00
flat		N/AN/A$40K$470.74MN/A2,700
GMVDF
G Medical Innovations
N/A$0.00
flat		N/AN/A$26K$4.42MN/A72
VRAYQ
ViewRay
N/AN/AN/AN/A$16K$102.21MN/A300
AFIB
Acutus Medical
N/A$0.00
+100.0%		N/A-80.0%$6K$7.16MN/A340

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:TTOO) was last updated on 8/14/2026 by MarketBeat.com Staff.
From Our Partners
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Trump’s New Currency Reset
Trump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 i...
Porter & Company | Sponsoredtc pixel
Buy These Stocks Before August 31st
Keith Kaplan has invested $17 million into his own AI research platform, now used by 180,000 investors worldwi...
TradeSmith | Sponsoredtc pixel
Ray Dalio: Buy Gold. Get Paid.
Ray Dalio, founder of Bridgewater Associates, is urging investors to hold 15% of their portfolio in gold and c...
Investors Alley | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Gold buyout deals have handed shareholders overnight gains up to 79 percent
Gold major acquisitions have repriced junior miners overnight, with past deals delivering gains from 40% to 1,...
Golden Portfolio | Sponsoredtc pixel
Who Really Gets Rich from IPOs?
Peter Thiel turned a $500,000 stake in Meta into nearly $1 billion by investing eight years before its IPO. Tr...
Weiss Ratings | Sponsoredtc pixel